The big question in administration of bispecific antibodies these days is how quickly they can move to the outpatient setting ...
ADC Therapeutics (NYSE:ADCT) executives used a recent fireside chat at the H.C. Wainwright conference to outline the ...
New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states. The methods of subtyping diffuse large B-cell lymphoma (DLBCL) have changed over ...
New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk. The ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We are so lucky in DLBCL to make more rapid ...
Genmab A/S (NASDAQ:GMAB) executives outlined a slate of late-stage clinical catalysts expected in 2026, highlighting multiple ...
Follow-up data from the EPCORE NHL-1 trial lend further support to the efficacy and safety of single-agent epcoritamab (Epkinly) in the treatment of relapsed/refractory diffuse large B-cell lymphoma ...
Add Yahoo as a preferred source to see more of our stories on Google. The trial evaluated epcoritamab as a monotherapy against R-GemOx Danish biotechnology company Genmab has announced top line ...
At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as frontline monotherapy for elderly patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results